Taro and Alkem to Collaborate on Product Development For U.S. and Other Markets
29. Dezember 2005 07:00 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Dec. 29, 2005 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) (the "Company") reported today that it has entered into an agreement with Alkem Laboratories Ltd....
Taro Receives Approval For Mupirocin Ointment USP, 2% ANDA
23. September 2005 12:50 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Sept. 23, 2005 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. has received approval from the U.S. Food and...
Taro Receives Approval for Halobetasol Propionate Cream, 0.05% ANDA
05. August 2005 07:00 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Aug. 5, 2005 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. has received approval from the U.S. Food and Drug...
Taro to Report First Quarter 2005 Results and Conduct Conference Call on April 26, 2005
20. April 2005 16:04 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., April 20, 2005 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (NASDAQ:TARO) intends to report financial results for the first quarter of 2005 prior to the NASDAQ market opening...
Taro to Report 4th Quarter and Full Year 2004 Results and Conduct Conference Call on February 24, 2005
22. Februar 2005 12:58 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Feb. 22, 2005 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) intends to report financial results for the fourth quarter and full year 2004 prior to the Nasdaq...
Taro Receives Approval for Hydrocortisone Butyrate Ointment, 0.1% ANDA
27. Dezember 2004 17:03 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Dec. 27, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that it has received approval from the U.S. Food and Drug Administration for its...
Taro USA Receives Approval for Halobetasol Propionate Ointment, 0.05% ANDA
16. Dezember 2004 14:50 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Dec. 16, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA"), its U.S. affiliate, has received...
Taro USA Receives Approval For Mometasone Furoate Ointment, USP 0.1% ANDA
06. Dezember 2004 07:00 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Dec. 6, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA"), its U.S. affiliate, has received...
Taro USA Receives Approval For Mometasone Furoate Ointment, USP 0.1% ANDA
03. Dezember 2004 20:07 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Dec. 3, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA"), its U.S. affiliate, has received...
Taro Reports `A+' Bond Rating In Israel
22. November 2004 07:00 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Nov. 22, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. ("Taro," "the Company," (Nasdaq:TARO)) today reported that it has received an "A+" rating from Maalot, the Israeli...